×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
Yahoo Finance
Moleculin CEO, Walter Klemp highlights Annamycin differentiation in the current AML treatment landscape and potential opportunity FRENCHTOWN...
3 days ago
Moleculin Biotech Shares Corporate Direction Insights - TipRanks.com
Tipranks
Moleculin Biotech (MBRX) just unveiled an update. Moleculin Biotech, Inc. has released a corporate presentation on its website,...
3 days ago
Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
PR Newswire
PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad...
1 month ago
Moleculin Announces Reverse Stock Split
PR Newswire
PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a...
1 month ago
Companies Like Moleculin Biotech (NASDAQ:MBRX) Are In A Position To Invest In Growth
Yahoo Movies Canada
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
5 days ago
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the ...
PR Newswire
PRNewswire/ -- Moleculin Biotech, Inc. (NASDAQ: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad...
4 months ago
Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
Yahoo Finance
A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn.
4 months ago
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid ...
PR Newswire
Next-generation non-cardiotoxic anthracycline Annamycin with notable signs of clinical efficacy in AML in combination with Cytarabine...
1 week ago
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
PR Newswire
PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad...
1 month ago
Moleculin Reports Full Year 2023 Financial Results
PR Newswire
PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad...
1 month ago